RFK Jr drives pharma to 15-year low
This article is so good
it's for premium members only.
Does that sound like you?
PREMIUM
ONLY $30/MONTH
BILLED ANNUALLY OR $35 MONTHLY
All BASIC features, plus:
- Premium Articles: Dive into subscriber-only content, market analysis, and insights that keep you ahead of the game.
- Access to our Private X Account, The Market Ear analysis, and Newsquawk
- Ad-Free Experience: Enjoy an uninterrupted browsing experience.
PROFESSIONAL
ONLY $125/MONTH
BILLED ANNUALLY OR $150 MONTHLY
All PREMIUM features, plus:
- Research Catalog: Access to our constantly updated research database, via a private Dropbox account (including hedge fund letters, research reports and analyses from all the top Wall Street banks)
On a losing streak - and then comes RFK
The pharma sector has been facing a growing number of uncertainties which are increasingly getting reflected in biopharma's collapsing multiples. Generalists were already abandoning the sector, as evidenced by 9 straight weeks of HC sector underperformance even before this week's RFK Jr news. Let's have a look at the disaster sector of 2024.